33 results about "Diagnostic screening" patented technology

Endometrial cancer (EC) is the most common gynecologic cancer in developed countries and the fourth most common cancer affecting women in the US. In contrast to other cancers, rates of EC continue to rise, and there are indications that social determinants of health and race and / or ethnicity contribute to risk. Thus, the methods described herein provide a non-invasive means of measuring biomarkers in the local cervicovaginal microenvironment. These novel biomarkers may be used for diagnosing and / or predicting women who are "at risk" for the development and progression of endometrial cancer (EC; e.g., EC type 1). Specifically, the methods herein may include obtaining a cervicovaginal lavage (CVL) or vaginal swab sample from a patient and producing a profile of at least five or more biomarkers from the collected sample.

The invention belongs to the technical field of biology, and particularly relates to a Parkinson's disease diagnosis kit based on a peripheral red blood cell alpha-synuclein RT-QuIC technology and application of the Parkinson's disease diagnosis kit. The Parkinson's disease diagnostic kit based on the peripheral red blood cell alpha-synuclein RT-QuIC technology comprises a substrate protein, a reaction reagent, a negative reference substance and a positive reference substance, and a sample is selected from red blood cells in blood. The RT-QuIC technology is applied to diagnosis of neurodegenerative diseases, particularly, the sowing activity of pathological alpha-Syn protein is detected in blood red blood cell samples of PD patients of Chinese population for the first time, and the kit has extremely high sensitivity and specificity and provides important reference value for diagnosis and screening of PD. The invention provides a rapid, efficient and accurate diagnostic kit for diagnosis of Parkinson's disease, the kit can be used for accurately detecting Parkinson's disease patients and healthy control, and powerful technical support is provided for clinical diagnosis of the Parkinson's disease patients.

The invention belongs to the technical field of biomedicine, and particularly relates to a gene methylation marker and application thereof. The invention discloses the ELTD1 gene methylation marker for the first time, the ELTD1 gene methylation marker can be used for diagnosis, screening, monitoring, curative effect evaluation or prognosis evaluation of the lung cancer, the sensitivity is high, and the detection rate of the lung cancer is greatly improved.

The application discloses an image sharpening and enhancing method in cataract diagnosis screening, belongs to the field of image enhancement, and aims to improve the quality of cataract diagnosis screening images. The method first collects images to construct a cataract diagnosis screening image dataset, then extracts optimal illumination components and reflection components by using an interactive separation module based on structure perception through structure response distillation and a joint optimization target strategy, and then enhances the illumination components by using an illumination component structure adjustment module and improves the details of the reflection components by using a reflection component high-frequency residual enhancement module, integrates all the modules to construct an image enhancement model, and finally inputs the dataset into the model to output high-resolution cataract diagnosis screening images.

The invention provides a method for pooling samples prior to a diagnostic screen for a non-infectious disease. The method includes pooling only a portion of the obtained samples and storing the other portion for later use. Pooling samples represents a more time and cost-effective way to perform diagnostic screening.

The invention relates to the field of gene detection, in particular to a molecular marker for diagnosis, screening and risk prediction of early lung cancer. According to the present invention, the substance specifically binding to SPATA18 is selected from one or more of an antibody, a primer or a probe; the substance specifically binding to SPATA18 provided by the invention can realize diagnosis, screening and risk prediction of early lung adenocarcinoma, and fills the blank of risk and prognosis prediction of early non-invasive adenocarcinoma clinically; abnormities on the molecular level can be detected in the early stage of cancer development, and earlier intervention and treatment opportunities can be provided, so that the treatment success rate is increased; according to the method, the number of targets is relatively small, the stability is theoretically higher than that of other multi-target detection after the sample amount is increased, more accurate cancer risk assessment can be provided, the cancer progress probability of a patient can be better predicted, and making of a more accurate treatment plan is facilitated.

The present invention refers an in vitro method for inducing differentiation of human pluripotent stem cells (hPSCs) generating hindbrain neurons and compositions thereof. The invention also refers to the hindbrain neurons and compositions thereof for use in diagnostic screening and for use in the prevention and / or treatment of neurological disorders.

The invention provides a method for sample pooling prior to diagnostic screening for non-infectious diseases. The method comprises pooling only a portion of the obtained sample and storing another portion for later use. Sample pooling represents a more time and cost efficient way of performing diagnostic screening.

The invention relates to an occupational pneumoconiosis diagnosis and screening method. The method comprises the following steps: (1) data preparation; (2) carrying out graying processing on the collected X-ray film image; (3) extracting texture features from the preprocessed image by using a gray level co-occurrence matrix (GLCM) algorithm; (4) carrying out screening and dimension reduction processing on the extracted GLCM features; (5) constructing a CNN model, and upgrading and optimizing a residual network architecture; (6) training the CNN model by using the marked data set, and evaluating the performance of the model by using a cross validation method; and (7) inputting the trained CNN model for diagnosis screening. According to the method, gray-level co-occurrence matrix feature extraction is combined with the CNN model, a residual network architecture is upgraded and optimized for diagnosis and screening of occupational pneumoconiosis, the identification precision and the operation speed are improved, and the method is very suitable for research of pneumoconiosis.

The invention discloses a pathological section diagnosis screening analysis method based on a deep neural network, and the method comprises the steps: S1, obtaining the digital image data of a pathological section, and carrying out the preprocessing, and forming an image data set; s2, constructing a three-dimensional space-time Transform network model, obtaining feature images in a space-time dimension, and forming an image feature set; s3, model parameters pre-trained on the large-scale image data set are migrated to the constructed three-dimensional space-time Transform network model through migration learning, and the model is optimized; s4, training the fine-tuned model by using the labeled pathological section image data set; and S5, inputting a pathological section image to be diagnosed and screened into the trained model, and outputting a diagnosis result. According to the method, the diagnosis result is rapidly and accurately output and visually displayed, and the pathological diagnosis efficiency and accuracy are improved.

This invention discloses an anti-CD5 protein nanobody and its applications, relating to the field of nanobody biosynthesis technology. Utilizing a camel-derived nanobody library and targeting mouse CD5 protein, this invention employs phage display technology for in vitro enrichment and panning. Camel-derived nanobody sequences targeting CD5 protein are obtained through monoclonal high-throughput ELISA screening. These five nanobody sequences can be used to detect CD5 protein expression, for the diagnosis and screening of related tumors, and also for the preparation of drugs to treat related tumors.

The application discloses a radial multilayer microneedle sensing system and method for single follicular unit microenvironment analysis, and belongs to the field of skin appendage detection and biological micro-electro-mechanical systems. The system comprises a positioning hole integrated with an optical collimation unit, concentric ring microneedles with a length ratio within a certain range, ring compression protruding structures between the microneedles, a differential negative pressure sampling module and a detection electrode modified with an aptamer probe, which can accurately position the follicle, perform layered puncture, construct a hydraulic barrier to prevent cross-flow, isolate and extract interstitial fluid between deep and shallow layers and target detection of disease markers such as androgen alopecia. The method comprises the steps of optical targeting positioning, compression sealing puncture, differential sampling, in-situ detection and gradient index calculation. The application can improve the spatial detection resolution of the markers, solve the problems of signal dilution and subcutaneous cross-flow, and provide a quantitative tool for follicular pathological research and drug non-diagnostic screening.

A system for diagnostic screening of a chronic disease includes a test matrix and a user device. The test matrix has a calibration surface including one or more calibration elements and one or more reagents. The user device has image capturing and processing capabilities configured to capture an image and a processor configured to locate, based on the plurality of calibration elements, the test matrix in the image, determine if the test matrix indicates the presence of the chronic disease by comparing a detected contrast of the one or more reagents with the test matrix to an augmented reality trained database, and generate a screening report based on the determination.

An integrated device and method are disclosed for single-step extraction and affinity capture of analytes from dried biological sample carriers. The device defines an internal cavity configured to fully receive a sample carrier comprising a dried biological sample, such as a dried blood spot. Multiple analyte-specific capture elements are immobilized on a surface within the cavity. Upon introduction of an extraction buffer, analytes are released from the dried sample and concurrently captured by the immobilized capture elements within the same device, eliminating intermediate elution, transfer, or washing steps. Continuous depletion of free analyte within the capture zone promotes further analyte release from the dried sample, enabling efficient equilibrium-driven extraction. The device is compatible with immunoassay and other affinity-based detection formats and supports proteins, nucleic acids, and small-molecule analytes. The disclosed device reduces processing time, handling complexity, and sample loss, and is suitable for diagnostic, screening, and monitoring applications.

The present invention provides systems, instruments, and methods for determining genetic or molecular distortions in a biological sample from an organism. Biological samples including free DNA fragments are analyzed to identify imbalances present in chromosomal regions, e.g., due to tumor chromosome deletion and / or amplification. Multiple loci are used for analysis of individual chromosomal regions. Such imbalances can then be used to diagnose (screen) cancer as well as prognosis of cancer patients, or to detect a patient's pre-exacerbation health status or to monitor changes in a patient's pre-exacerbation health status. Diagnosis, screening, prognosis, and monitoring can be provided using the severity of genomic imbalances, as well as the number of regions of imbalance. Systematic analysis of non-overlapping chromosome segments can provide a universal cancer screening means. Furthermore, the patient can be examined at different points in time to track one or more chromosomal regions and the severity of each of the numerous chromosomal regions and the number of chromosomal regions exhibiting chromosomal aberrations, therefore, cancer screening, prognosis diagnosis and lesion process monitoring (for example, after treatment) can be carried out.

The invention discloses a biomarker combination, application, a product and a system for detecting local progression stage gastric cancer, and relates to the technical field of biological medicines. The biomarker combination for diagnosis, screening, illness state monitoring and / or drug curative effect monitoring of the local progression stage gastric cancer comprises the following proteins: SRI, SMARCA5, TPD52, PLBD1, PDLIM7, COL18A1, ACTR3, ALDH1A1, EHD2, ARF5, DNPEP, OGFR, PBXIP1, GOT1, SNW1, PRKAR1A, DCTN2, TMEM109, ANPEP and MOV10. According to the invention, a 20-panel proteome prediction model is constructed for the first time, and compared with PDL1 expression, the 20-panel proteome prediction model has better capability of predicting treatment response crowds. Compared with PDL1 expression which is most commonly used for judging the curative effect of gastric cancer immunotherapy clinically at present, the sensitivity, the specificity, the AUC and the like of the 20-Panel proteome for predicting pathological response people are obviously improved. The method is beneficial for efficiently and accurately predicting and screening sensitive people who receive neoadjuvant chemotherapy and immunotherapy on the gastric cancer in the local development stage before treatment, and the most suitable treatment scheme is selected.

The invention provides methods for assessment of tumor biomarkers using target-enriched multiplexed parallel analysis. The methods of the invention utilize Target Capture Sequences (TACS) to thereby enrich for target sequences of interest, followed by massive parallel sequencing and statistical analysis of the enriched population. The methods can be used with DNA samples from a patient, such as a tissue biopsy or plasma sample (liquid biopsy), for detection of the presence of tumor biomarkers, e.g., for purposes of diagnosis, screening, therapy selection and / or treatment monitoring. Kits for carrying out the methods of the invention are also provided.

The application discloses a LAMP primer and probe combination, a kit and a detection method for simultaneously identifying three viruses of chicken parvovirus, chicken infectious anemia virus (CIAV) and fowl adenovirus serotype 4 (FADV4), and comprises three sets of primer groups corresponding to the three viruses and three probes of different colors; a detection reaction process only comprises isothermal amplification and termination, and finally, a triple fluorescence LAMP reaction is completed in a same reaction tube; after the reaction, the three viruses can be identified and diagnosed according to different colors of the three probes; the minimum detection capability is 1 copy / muL of virus DNA; the whole detection process is simple, rapid, low in cost, high in specificity and sensitivity, small in interference, capable of realizing on-site pathogen detection, and suitable for large-scale diagnostic screening of chicken groups.

The invention discloses an image sharpening and enhancing method in cataract diagnosis and screening, belongs to the field of image enhancement, and aims to improve the quality of cataract diagnosis and screening images. The method comprises the following steps: firstly, collecting images to construct a cataract diagnosis and screening image data set, and then, carrying out structural response distillation and joint optimization of a target strategy to obtain a clear image; an interactive separation module based on structure perception is used for extracting an optimal illumination component and an optimal reflection component, then the illumination component is enhanced through an illumination component structure adjustment module, details of the reflection component are improved through a reflection component high-frequency residual enhancement module, all the modules are integrated to construct an image enhancement model, and finally a data set is input to the model. And outputting a high-resolution cataract diagnosis screening image.

This disclosure relates generally to and, more particularly, to assessment of PCOS. Polycystic ovarian syndrome (PCOS) is a hormonal disorder common among women of reproductive age that causes infertility and affects overall health of the woman. As PCOS is common and curable cause of infertility, an efficient early screening to assess a potential risk of PCOS can ensure early treatment. The current state-of-the-art techniques include diagnostic, screening solutions, imaging techniques which are invasive, complex, expensive. The disclosure is a supervised machine learning algorithm on the samples of individuals to arrive at a panel of biological features / indicators / markers / signatures that can accurately stratify / classify / group individuals into ‘PCOS’ and ‘healthy’ based upon the differences in the composition of the gut / oral microbial communities.

Provided is a use of an IFP35 family protein in diagnosis of sepsis or related diseases thereof. Provided is an IFP35 family protein as a marker for diagnosis, screening, severity assessment, monitoring, efficacy assessment, or prognosis assessment of sepsis or related diseases thereof, and non-sepsis infectious diseases. By measuring the content, the expression level and / or activity of the IFP35 family protein, diagnosis, screening, severity assessment, monitoring, efficacy assessment, or prognosis assessment of sepsis or related diseases thereof, and non-sepsis infectious diseases can be realized.

The invention provides a method for pooling samples prior to a diagnostic screen for a non-infectious disease. The method includes pooling only a portion of the obtained samples and storing the other portion for later use. Pooling samples represents a more time and cost-effective way to perform diagnostic screening.

Adenomyosis is a highly prevalent yet enigmatic disease that can be diagnosed only via histopathology among women undergoing hysterectomy, thus, leading to underdiagnosis. Unfortunately, research on adenomyosis has been limited due to a variety of challenges, and little work has been done on non-invasive diagnostics for adenomyosis. Currently, there is no FDA-approved non-invasive method for early detection of adenomyosis. By integrating immunoassays and metabolomics analyses, candidate biomarkers for the non-invasive diagnosis of adenomyosis in cervicovaginal lavages have been identified. Thus, methods for non-invasive diagnostic, screening, and early detection of adenomyosis in patients are described herein.

The invention relates to the technical field of biological detection, and particularly discloses a helicobacter pylori antigen chromatography detection test strip, a kit and application. The helicobacter pylori antigen chromatography detection test strip provided by the invention comprises a PVC (Polyvinyl Chloride) bottom plate, a sample pad, a combination pad, a nitrocellulose membrane and a water absorption pad are arranged on the PVC bottom plate; the combination pad contains a mouse anti-helicobacter pylori monoclonal antibody I marked by colloidal gold; a detection line T and a quality control line C are arranged on the nitrocellulose membrane; the detection line T is coated with a mouse anti-helicobacter pylori monoclonal antibody II, and the quality control line C is coated with a goat anti-mouse IgG polyclonal antibody; the preparation method of the conjugate pad comprises conjugate pad pretreatment, specifically, the conjugate pad is soaked in conjugate pad pretreatment liquid for 30-60 min and dried, and the pretreated conjugate pad is obtained. The helicobacter pylori antigen chromatography detection test strip provided by the invention has the advantages of high sensitivity, strong specificity, good stability and the like, can realize diagnosis and screening of helicobacter pylori infection, and has a wide application prospect.

The present invention provides systems, instruments and methods for determining genetic or molecular aberrations in biological samples from an organism. Biological samples, including cell-free DNA fragments, are analyzed to identify imbalances present in chromosomal regions, for example, due to tumor chromosomal deletions and / or amplifications. Multiple loci are used for the analysis of each chromosomal region. Such imbalances can then be used to diagnose (screen for) cancer and to prognose cancer patients, or to detect or monitor changes in a patient's health status prior to deterioration. Diagnoses, screens, prognoses and monitoring can be provided using the severity of genomic imbalances and the number of imbalanced regions. Systematic analysis of non-overlapping chromosomal segments can provide a general cancer screening approach. Furthermore, a patient can be tested at different time points to track the severity of each of one or more chromosomal regions and the number of chromosomal regions exhibiting chromosomal aberrations, thereby enabling screening, prognosing and monitoring of cancer progression (e.g., following treatment).

The invention discloses application of a biomarker IFNL3 in preparation of a detection product for gastric cancer or gastric precancerous lesions. It is found for the first time that IFNL3 can be used for predicting early detection and progress detection of gastric cancer, and diagnosis and prognosis values in early detection and monitoring of gastric cancer can be evaluated through the expression level of plasma IFNL3. The IFNL3 is used for early detection of gastric cancer and dynamic monitoring of disease progression, is excellent in detection sensitivity and specificity, high in accuracy and stability, simple, convenient and rapid in method and low in cost, has important clinical application value, provides a new method for diagnosis, screening and monitoring of gastric cancer and gastric precancerous lesions, and is suitable for clinical large-scale popularization and application.

The invention provides a target nucleic acid molecule for identifying multiple cancer species and application of the target nucleic acid molecule. A group of methylated target nucleic acid molecules for multi-tumor (Pan-Cancer) diagnosis are screened and demonstrated, the methylated target nucleic acid molecules have significant methylation state differences in tumor samples, and people with high tumor risk can be judged on the basis of the methylated target nucleic acid molecules. When the target nucleic acid molecule is jointly applied to detection, unexpected improvement of sensitivity and specificity is shown. The tumor target nucleic acid molecule disclosed by the invention can be used as a target nucleic acid molecule for clinical diagnosis, screening, typing, detection and prognosis of tumors, can also be used as a novel molecule for clinical auxiliary diagnosis or prognosis of tumors, and is widely applied to various different types of tumors.

Provided is a diagnostic screening method for early disease detection by analyzing a sample from an individual at a plurality of points in time.

The invention belongs to the technical field of biological medicine, and particularly relates to application of IFP35 family protein in diagnosis of sepsis or related diseases thereof. The invention discloses IFP35 family protein as a marker for diagnosis, screening, severity evaluation, monitoring, curative effect evaluation or prognosis evaluation of sepsis or related diseases thereof and non-sepsis infectious diseases for the first time. Diagnosis, screening, severity evaluation, monitoring, curative effect evaluation or prognosis evaluation of sepsis or related diseases thereof and non-sepsis infectious diseases can be realized by detecting the content, expression quantity and / or activity of IFP35 family proteins.

The invention belongs to the technical field of biomedicine, and discloses mascRNA for diagnosing, screening or evaluating acute coronary syndrome and application of mascRNA in preparation of products for diagnosing, screening or evaluating prognosis of acute coronary syndrome. The novel marker mascRNA provided by the invention has excellent stability, and brings convenience and low trauma to diagnosis of the acute coronary syndrome; the expression difference in plasma exosomes of patients with the acute coronary syndrome and people with normal coronary arteries is achieved, and the important value is achieved in the aspect of clinical diagnosis of the acute coronary syndrome (AUC is 0.763, and 95% CI is 0.702-0.824). Kaplan-Meier analysis and log-rank test data show that compared with a patient with low mascRNA expression, a patient with high mascRNA expression has a lower MACE-free survival rate (Plt; 0.001) in the formula (1).